Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14141622 | 0.88 | LMNA (0.48) | IGF1RALDH1A1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL30166910 | 0.88 | ALDH1A1 (0.42) | IGF1RHPGDALDH1A1MAPK1KMT2A | |
| SCHEMBL3132338 | 0.88 | IGF1R (0.46) | IGF1RHPGDALDH1A1MAPK1POLB | |
| SCHEMBL3141664 | 0.85 | IGF1R (0.48) | IGF1RHPGDALDH1A1MAPK1POLB | |
| SCHEMBL3139418 | 0.85 | IGF1R (0.48) | IGF1RHPGDALDH1A1MAPK1POLB | |
| SCHEMBL3136326 | 0.84 | CYP1A2 (0.46) | IGF1RHPGDALDH1A1MAPK1POLB | |
| SCHEMBL13480139 | 0.84 | HTT (0.46) | IGF1RHPGDALDH1A1MAPK1POLB | |
| SCHEMBL3139684 | 0.83 | HPGD (0.45) | IGF1RHPGDALDH1A1MAPK1POLB | |
| SCHEMBL13480223 | 0.83 | HTT (0.46) | IGF1RHPGDALDH1A1MAPK1POLB | |
| SCHEMBL140029 | 0.82 | IGF1R (0.50) | IGF1RHPGDALDH1A1MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778187-B | Synthesis method of Hainatinib intermediate and Hainatinib intermediate obtained by synthesis method | 烟台舜康生物科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-112778187-A | Synthesis method of Hainatinib intermediate and Hainatinib intermediate obtained by synthesis method | 烟台舜康生物科技有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-11-14 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-8329682-B2 | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-12-11 | — | — | US | disclosed |
| US-20120295887-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-11-22 | — | — | US | disclosed |
| US-20120295887-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-11-22 | — | — | US | disclosed |
| US-20120295887-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-11-22 | — | — | US | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
| EP-2157093-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-02-24 | — | — | EP | disclosed |
| EP-2157093-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | MTOR, PKN2, MAP3K15 | IGF1R 2072/4885HPGD 163/4885ALDH1A1 2707/4885 |
| US-20130303518-A1 | Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder | PRKACA, PACSIN2, PRKACB | IGF1R 1380/4885HPGD 3156/4885ALDH1A1 4203/4885 |
| US-20120295887-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USE THEREOF | DMPK, PKN2, AZI2 | IGF1R 2268/4885HPGD 1120/4885ALDH1A1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.